BOOK
Advances in Veterinary Oncology, An Issue of Veterinary Clinics of North America: Small Animal Practice, E-Book
(2014)
Additional Information
Book Details
Abstract
This issue focuses on new advances in oncology in treating dogs and cats. Topics include: Use of metronomic chemotherapy in veterinary cancer patients, Evidence-based integrative medicine in clinical veterinary oncology, The role of surgery in multimodality cancer therapy for small animals, Cancer screening tests for small animals, Antibiotic use in veterinary oncology patients, Tyrosine kinase inhibitors in veterinary oncology practice, Stereotactic radiosurgery/Advances in veterinary radiation therapy, Tumor vaccines in veterinary oncology practice, Chemotherapy safety in clinical veterinary oncology, Role of neutering in cancer development, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Advances in Veterinary Oncology\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Veterinary Clinics Of North America: Small Animal Practice\r | ix | ||
| Preface\r | xi | ||
| Errata\r | xiii | ||
| Metronomic Chemotherapy in Veterinary Patients with Cancer | 817 | ||
| Key points | 817 | ||
| Introduction | 817 | ||
| Targets of MC | 818 | ||
| Tumor Angiogenesis | 818 | ||
| Tumor Immunology | 820 | ||
| Other Potential Targets | 821 | ||
| Clinical trials investigating MC | 821 | ||
| Summary of Human Clinical Trials | 821 | ||
| Veterinary Clinical Trials | 822 | ||
| MC in clinical practice: challenges and future directions | 822 | ||
| Biomarkers for MC | 822 | ||
| Side Effects | 824 | ||
| Development of Drug Resistance | 825 | ||
| Practical Guidelines for Veterinary Patients with Cancer | 825 | ||
| Summary | 825 | ||
| References | 825 | ||
| Evidence-based Integrative Medicine in Clinical Veterinary Oncology | 831 | ||
| Key points | 831 | ||
| Herbs/botanics evaluated in dogs or in vitro canine cells | 833 | ||
| Herbs/botanics evaluated in vivo or in vitro in other species | 834 | ||
| Bioactive polysaccharides: fungi | 836 | ||
| Acupuncture | 838 | ||
| Dietary supplements evaluated in dogs or in vitro canine cells and relevant studies in other species or in vitro | 838 | ||
| Calcitriol | 839 | ||
| Retinoids | 839 | ||
| Antioxidants | 839 | ||
| Omega-3 Fatty Acids | 840 | ||
| Probiotics | 841 | ||
| Phytic Acid, Phytate, Myo-Inositol Hexaphosphate | 842 | ||
| Using IM in veterinary clinical oncology | 843 | ||
| Adverse reactions: drug-herb interactions | 843 | ||
| References | 844 | ||
| Role of Surgery in Multimodal Cancer Therapy for Small Animals | 855 | ||
| Key points | 855 | ||
| Preoperative evaluation | 856 | ||
| Surgical treatment | 856 | ||
| Surgical oncology principles | 857 | ||
| Role of the histopathologist | 858 | ||
| Chemotherapy and surgery | 859 | ||
| Combining radiotherapy with surgery | 860 | ||
| Response of normal tissue to radiation | 861 | ||
| Surgery of tissue to be irradiated | 863 | ||
| Operating in irradiated tissue | 865 | ||
| Summary | 867 | ||
| References | 867 | ||
| Cancer Screening Tests for Small Animals | 871 | ||
| Key points | 871 | ||
| Introduction | 871 | ||
| Tests for lymphoma | 872 | ||
| Veterinary Diagnostics Institute TKcanine | 872 | ||
| VDI TKFeline | 874 | ||
| Sensitest/Petscreen/Tri-Screen/Canine Lymphoma Blood Test | 875 | ||
| Polymerase Chain Reaction for Antigen Receptor Rearrangements | 877 | ||
| Tests for canine hemangiosarcoma | 878 | ||
| VDI TKcanine | 878 | ||
| Tests for canine transitional cell carcinoma | 878 | ||
| Veterinary Version of the Bladder Tumor Antigen Test | 878 | ||
| General cancer tests | 878 | ||
| OncoPet RECAF | 878 | ||
| P-glycoprotein Mutation | 879 | ||
| References | 880 | ||
| Antimicrobial Use in the Veterinary Cancer Patient | 883 | ||
| Key points | 883 | ||
| Antimicrobial use in the cancer patient | 883 | ||
| Antimicrobial use in the neutropenic patient | 883 | ||
| Risk factors | 884 | ||
| Febrile neutropenia management | 884 | ||
| Special considerations when initiating antimicrobial therapy in febrile, neutropenic patients | 885 | ||
| Prophylactic antimicrobial use | 886 | ||
| Prophylactic antimicrobial use after chemotherapy administration: “prevention antimicrobials” | 886 | ||
| Antimicrobial use in afebrile, neutropenic patients | 887 | ||
| Antimicrobial use in radiation therapy patients | 888 | ||
| Doxycycline and veterinary oncology patients | 889 | ||
| References | 890 | ||
| Small Molecule Inhibitors in Veterinary Oncology Practice | 893 | ||
| Key points | 893 | ||
| Introduction | 893 | ||
| Regulation of normal cell biology | 894 | ||
| Dysregulation of Proteins in Cancer Cells | 895 | ||
| Small Molecule Kinase Inhibitors: The Human Experience | 896 | ||
| Small molecule inhibitors in veterinary medicine | 898 | ||
| Toceranib (Palladia) | 898 | ||
| Toceranib in the Clinic | 898 | ||
| Phase 1 clinical trial | 898 | ||
| Results of the field study | 898 | ||
| Biological activity off label | 898 | ||
| Combination therapy with piroxicam | 899 | ||
| Combination therapy with vinblastine | 899 | ||
| Combination therapy with radiation | 899 | ||
| Role in metronomic therapy | 899 | ||
| Toceranib Dosing | 900 | ||
| Masitinib (Kinavet) and Imatinib | 900 | ||
| Management of Adverse Events Associated with Toceranib and Masitinib | 901 | ||
| Additional Small Molecule Inhibitors Under Investigation | 902 | ||
| Resistance to Small Molecule Inhibitors | 903 | ||
| Summary | 904 | ||
| References | 904 | ||
| Advances in Veterinary Radiation Therapy | 909 | ||
| Key points | 909 | ||
| Introduction | 909 | ||
| Radiation oncology in veterinary medicine: past to present | 910 | ||
| Biological principles and technical advances | 911 | ||
| The Introduction of Megavoltage Radiation Therapy | 912 | ||
| Manual Point-Dose Calculations | 912 | ||
| 3D-CRT | 913 | ||
| IMRT | 913 | ||
| Advanced Imaging for Better Tumor Localization During Planning | 914 | ||
| Image-Guided Radiation Therapy | 915 | ||
| DART | 916 | ||
| SRT | 917 | ||
| Future directions | 919 | ||
| References | 921 | ||
| Immunotherapy in Veterinary Oncology | 925 | ||
| Key points | 925 | ||
| Tumor immunology | 926 | ||
| Cellular Components | 926 | ||
| Immune Surveillance | 926 | ||
| Immune Evasion by Tumors | 927 | ||
| Nonspecific tumor immunotherapy | 927 | ||
| Biologic Response Modifiers | 927 | ||
| Recombinant Cytokines, Growth Factors, and Hormones | 928 | ||
| Cancer vaccines | 928 | ||
| References | 932 | ||
| Chemotherapy Safety in Clinical Veterinary Oncology | 941 | ||
| Key points | 941 | ||
| History of chemotherapy safety | 941 | ||
| Relevance to veterinary medicine | 942 | ||
| Protection motivation theory and lack of compliance | 943 | ||
| State legislation mandating compliance | 944 | ||
| Defining exposure and health risk: a method to the madness | 944 | ||
| Evidence of health risk: biological effect monitoring and reproductive concerns | 945 | ||
| Routes of exposure and persons at risk: environmental and biological monitoring | 948 | ||
| Hazard control and recommended health actions | 950 | ||
| Levels 1 and 2: Eliminate or Substitute the Hazard | 950 | ||
| Level 3: Engineering Controls | 951 | ||
| Level 4: Administrative Controls | 952 | ||
| Level 5: Personal Protective Equipment | 955 | ||
| Safe handling and administration of oral anticancer agents | 956 | ||
| Summary | 958 | ||
| Supplementary data | 959 | ||
| References | 959 | ||
| The Role of Neutering in Cancer Development | 965 | ||
| Key points | 965 | ||
| Introduction | 965 | ||
| Mammary tumors | 966 | ||
| Reproductive organ tumors and tumors treated by neutering | 967 | ||
| Osteosarcoma | 967 | ||
| Hemangiosarcoma | 968 | ||
| Lymphoma | 968 | ||
| Transitional cell carcinoma | 968 | ||
| Mast cell tumors | 969 | ||
| The influence of sterilization on lifespan | 969 | ||
| Critiques of the data presented | 970 | ||
| The practitioner’s dilemma | 970 | ||
| References | 971 | ||
| The Role of Clinical Trials in Veterinary Oncology | 977 | ||
| Key points | 977 | ||
| Introduction | 977 | ||
| Phases of drug development | 978 | ||
| Phase I (Dose-finding) Clinical Trials | 979 | ||
| Defining Adverse Events and Dose-limiting Toxicities | 979 | ||
| Client Considerations for a Phase I Study | 980 | ||
| Phase II (Activity/Efficacy) Clinical Trials | 980 | ||
| Client Considerations for a Phase II Study | 981 | ||
| Phase III (Comparative) Clinical Trials | 981 | ||
| Client Considerations for a Phase III Study | 981 | ||
| Phase 0 Clinical Trials | 982 | ||
| Phase IV (After-market) Clinical Trials | 982 | ||
| Role of clinical trials for clients and their pets | 982 | ||
| Benefits of Clinical Trial Participation | 982 | ||
| Barriers to Clinical Trial Enrollment | 983 | ||
| Ethics/Patient Protection | 983 | ||
| Owner Informed Consent | 983 | ||
| Appropriate Trial Design/Good Clinical Practice Guidelines | 984 | ||
| Institutional Animal Care and Use Committee/Clinical Trials Review Board | 985 | ||
| Data Safety Monitoring Board | 985 | ||
| Resources | 985 | ||
| Summary | 986 | ||
| References | 986 | ||
| Pain Management in Veterinary Patients with Cancer | 989 | ||
| Key points | 989 | ||
| Introduction | 989 | ||
| Pain generation, categorization, and recognition | 990 | ||
| Pain Pathophysiology | 990 | ||
| Pain Categorization | 990 | ||
| Pain Recognition | 991 | ||
| Pharmacologic treatment strategies | 992 | ||
| General Guidelines | 992 | ||
| Specific Drug Classes and Mechanisms of Action | 994 | ||
| NSAIDs | 994 | ||
| Opioids | 994 | ||
| N-methyl d-aspartate antagonists | 994 | ||
| Combination analgesics | 994 | ||
| Anticonvulsant drugs | 995 | ||
| Tricyclic antidepressants | 995 | ||
| Bone cancer pain | 995 | ||
| Unique Aspects | 995 | ||
| Strategies to Alleviate Malignant Bone Pain | 996 | ||
| Palliative radiation therapy | 996 | ||
| Stereotactic radiosurgery | 996 | ||
| Radiopharmaceuticals | 996 | ||
| Aminobisphosphonates | 997 | ||
| Supportive care | 997 | ||
| Summary | 998 | ||
| References | 998 | ||
| Index | 1003 |